A recent study has shown that ablation of nSMase in the AD mouse model 5xFAD improves AD pathology by reducing brain exosomes, ceramide levels, Aβ, phosphorylated Tau and plaques [148]. This evidence concerns the gene MAPT and Alzheimer disease.